Tests sauna therapy in people with heart failure during cardiac rehabilitation

Trial details

Who runs it

Central Hospital, Nancy, France

Trial code

NCT07468344

Record updated

29 October 2026

Original description

This study aims to evaluate the effect of sauna therapy on congestion levels during cardiac rehabilitation in patients with heart failure who have an impaired or moderately impaired ejection fraction, compared to standard cardiac rehabilitation care. To investigate this, patients with reduced cardiac function who are hospitalized as part of a cardiac rehabilitation program will be included. These patients will be randomly assigned to two groups: standard cardiac rehabilitation program (control group) and sauna group (intervention group). The study will also assess whether this approach could allow for a reduction in the dose of diuretics, which are commonly used to remove excess fluid, thereby helping to avoid certain side effects. The expected benefits include a reduction in symptoms such as shortness of breath and swelling, improvements in quality of life and physical fitness, and enhanced blood vessel function.Read full original descriptionShow less

Impact of Sauna Therapy on Congestion and Loop Diuretic Adjustment in Patients With Heart Failure

This study aims to evaluate the effect of sauna therapy on congestion levels during cardiac rehabilitation in patients with heart failure who have an impaired or moderately impaired ejection fraction, compared to standard cardiac rehabilitation care. To investigate this, patients with reduced cardiac function who are hospitalized as part of a cardiac rehabilitation program will be included. These patients will be randomly assigned to two groups: standard cardiac rehabilitation program (control group) and sauna group (intervention group). The study will also assess whether this approach could allow for a reduction in the dose of diuretics, which are commonly used to remove excess fluid, thereby helping to avoid certain side effects. The expected benefits include a reduction in symptoms such as shortness of breath and swelling, improvements in quality of life and physical fitness, and enhanced blood vessel function.

Inclusion: Age ≥ 18 years; Heart failure with ejection fraction <50% confirmed by an echocardiogram within the past year; NYHA class II-III; Loop diuretic dose ≥ 40 mg/day of furosemide (or equivalent) for at least 30 days; NT-proBNP > 400 pg/ml or BNP > 100 pg/ml; Estimated glomerular filtration rate (eGFR) ≥ 20 ml/min/1.73 m²; Patient scheduled for a hospital-based cardiac rehabilitation program for a minimum of 3 weeks; Person who has undergone a preliminary clinical examination suitable for clinical research; Person affiliated with a social security system or a beneficiary of such a system; Person who has received complete information about the organization of the clinical research and has signed informed consent.

Exclusion: Person presenting a contraindication to sauna therapy (for example, intolerance to heat); Person subject to Articles L. 1121-5, L. 1121-7, and L. 1121-8 of the Public Health Code (applicable in France) :- pregnant, giving birth, or breastfeeding woman , minor (non-emancipated), person adult subject to a legal protection measure (guardianship, curatorship, judicial protection) , adult unable to express consent, persons deprived of liberty by judicial or administrative decision, persons receiving psychiatric care under Articles L. 3212-1 and L. 3213-1…; Active infection, liver disease, or peripheral vascular disease; Acute coronary syndrome or recent stroke (<90 days); Serum sodium < 130 mmol/L; Serum potassium > 5.5 mmol/L; Participation in another interventional clinical trial; Person who objects to the processing of their data for quality control purposes.

ClinicalTrials.gov NCT07468344